UroGen Pharma Ltd. URGN
26.31 USD +1.56 (+6.30%)
At closeNov 9, 2026, 4:46 PM EST
26.83 +0.52 +1.98%
After hours · Nov 9, 4:46 PM ET
24.72 Day range 26.84
16.50 52-week range 50.81
- YTD
- +12.34%
- 1 year
- +13.21%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 60.71 +130.8% upside
Now 26.31
- Target (low)
- 54.00
- Target (mean)
- 60.71
- Target (high)
- 75.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.43 | 0.13 – 0.64 | -0.53 | +181.1% | 106.57M | +181.6% | 6 |
| Next quarter | 0.35 | 0.01 – 0.68 | -0.47 | +174.5% | 115.00M | +125.7% | 5 |
| Current year | -0.312 | -0.64 – -0.13 | -3.19 | +90.2% | 318.93M | +190.5% | 5 |
| Next year | 2.63 | 1.05 – 4.64 | -0.312 | +941.6% | 536.07M | +68.1% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 19, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 16, 2026 | Oppenheimer | Maintained | Outperform | Outperformer |
| Jun 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 7, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 31, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Mar 2, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Jan 23, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Oct 27, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 27, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Oct 3, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |
| Aug 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 7, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Aug 5, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jul 8, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 7, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jun 16, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Jun 13, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jun 13, 2025 | Guggenheim | Maintained | Buy | Buy |
| Jun 13, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 12, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jun 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |